View ValuationABL Bio 将来の成長Future 基準チェック /36ABL Bio利益と収益がそれぞれ年間49%と11.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-12.8% 47.2%なると予測されています。主要情報49.0%収益成長率47.24%EPS成長率Biotechs 収益成長37.3%収益成長率11.1%将来の株主資本利益率-12.84%アナリストカバレッジLow最終更新日29 Apr 2026今後の成長に関する最新情報Breakeven Date Change • Mar 17No longer forecast to breakevenThe 5 analysts covering ABL Bio no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of ₩10.9m in 2027. New consensus forecast suggests the company will make a loss of ₩16.0m in 2027.Major Estimate Revision • Nov 29Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩311 to ₩236 per share. Revenue forecast steady at ₩105.7m. Net income forecast to grow 54% next year vs 42% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩102,833 to ₩124,500. Share price rose 5.1% to ₩188,000 over the past week.すべての更新を表示Recent updatesBreakeven Date Change • Mar 17No longer forecast to breakevenThe 5 analysts covering ABL Bio no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of ₩10.9m in 2027. New consensus forecast suggests the company will make a loss of ₩16.0m in 2027.お知らせ • Mar 17ABL Bio Inc., Annual General Meeting, Mar 27, 2026ABL Bio Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 456, bongeunsa-ro, gangnam-gu, seoul South KoreaNew Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (₩16b net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Jan 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: ₩29b Forecast net loss in 2 years: ₩13b This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (₩13b net loss in 2 years).お知らせ • Jan 09ABL Bio Inc. announced that it has received KRW 21.7244227 billion in funding from Eli Lilly and CompanyOn January 9, 2026, ABL Bio Inc. closed the transaction. The company issued 172,553 common shares at an issue price of KRW 125,900 for gross proceeds of KRW 21,724,422,700.Major Estimate Revision • Nov 29Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩311 to ₩236 per share. Revenue forecast steady at ₩105.7m. Net income forecast to grow 54% next year vs 42% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩102,833 to ₩124,500. Share price rose 5.1% to ₩188,000 over the past week.Reported Earnings • Nov 13Third quarter 2025 earnings released: ₩395 loss per share (vs ₩274 loss in 3Q 2024)Third quarter 2025 results: ₩395 loss per share (further deteriorated from ₩274 loss in 3Q 2024). Revenue: ₩1.44b (down 82% from 3Q 2024). Net loss: ₩21.3b (loss widened 62% from 3Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: ₩820 (vs ₩238 loss in 2Q 2024)Second quarter 2025 results: EPS: ₩820 (up from ₩238 loss in 2Q 2024). Revenue: ₩75.7b (up ₩67.3b from 2Q 2024). Net income: ₩39.8b (up ₩51.2b from 2Q 2024). Profit margin: 53% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 153 percentage points per year, which is a significant difference in performance.分析記事 • Aug 08Health Check: How Prudently Does ABL Bio (KOSDAQ:298380) Use Debt?KOSDAQ:A298380 1 Year Share Price vs Fair Value Explore ABL Bio's Fair Values from the Community and select yours...New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.分析記事 • Mar 26ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Mar 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩1,156 loss per share (further deteriorated from ₩55.00 loss in FY 2023). Revenue: ₩33.4b (down 49% from FY 2023). Net loss: ₩55.5b (loss widened ₩52.9b from FY 2023). Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Mar 14ABL Bio Inc., Annual General Meeting, Mar 28, 2025ABL Bio Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 20, pangyo-ro 289beon-gil, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Nov 20Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%ABL Bio Inc. ( KOSDAQ:298380 ) shares have had a horrible month, losing 30% after a relatively good period beforehand...Reported Earnings • Nov 14Third quarter 2024 earnings released: ₩1,095 loss per share (vs ₩86.00 loss in 3Q 2023)Third quarter 2024 results: ₩1,095 loss per share (further deteriorated from ₩86.00 loss in 3Q 2023). Revenue: ₩7.94b (down 7.4% from 3Q 2023). Net loss: ₩52.5b (loss widened ₩48.4b from 3Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 36% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩238 loss per share (vs ₩217 loss in 2Q 2023)Second quarter 2024 results: ₩238 loss per share (further deteriorated from ₩217 loss in 2Q 2023). Revenue: ₩8.44b (down 1.7% from 2Q 2023). Net loss: ₩11.4b (loss widened 10% from 2Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in South Korea.分析記事 • May 29Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Apr 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 74% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).Reported Earnings • Mar 19Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: ₩55.00 loss per share (down from ₩67.00 profit in FY 2022). Revenue: ₩65.5b (down 2.6% from FY 2022). Net loss: ₩2.65b (down 183% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.8%. Revenue is expected to decline by 44% p.a. on average during the next 2 years, while revenues in the Biotechs industry in South Korea are expected to grow by 18%.分析記事 • Feb 26Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Jan 29New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 81% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩18,830, the stock trades at a trailing P/E ratio of 38.2x. Average forward P/E is 42x in the Biotechs industry in South Korea. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩16,520, the stock trades at a trailing P/E ratio of 33.5x. Average forward P/E is 34x in the Biotechs industry in South Korea. Total loss to shareholders of 32% over the past three years.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩20,750, the stock trades at a trailing P/E ratio of 42.1x. Average forward P/E is 42x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.お知らせ • Aug 05ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific AntibodyABL Bio Inc. announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea'sMinistry of Food and Drug Safety (MFDS). The Phase 1 clinical trial is an open-label, multi-center dose escalation and dose expansion study designed to evaluate the safety, tolerability, maximum tolerated dose (MTD) and preliminary efficacy of ABL501 in patients with advanced or metastatic solid tumors. ABL501 uses Grabody-I platform technology to simultaneously block PD-L1 and LAG-3-mediated T cell inhibition. Preclinical results demonstrate a synergistic increase of T cell activation that is higher than the enhancements induced by combination of anti-PD-L1 and LAG-3. ABL501 also showed a good safety profile in monkeys.分析記事 • Mar 31We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Feb 17New 90-day low: ₩21,400The company is down 17% from its price of ₩25,800 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.分析記事 • Jan 20Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...分析記事 • Dec 16Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 17New 90-day low: ₩22,300The company is down 27% from its price of ₩30,700 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: ₩27,550The company is down 5.0% from its price of ₩29,050 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.業績と収益の成長予測KOSDAQ:A298380 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202886,000-23,00016,00034,000212/31/2027114,5401,75019,40021,380512/31/202694,1201,00035,00052,00053/31/202690,321-24,1366,43319,955N/A12/31/202579,350-37,806-61,924-41,253N/A9/30/202588,437-28,645-54,641-33,185N/A6/30/202594,931-20,522-44,776-23,584N/A3/31/202527,631-71,706-95,079-80,249N/A12/31/202433,403-55,529-78,461-69,403N/A9/30/202432,321-49,041-81,451-71,189N/A6/30/202432,955-40,003-73,541-64,894N/A3/31/202433,103-38,952-67,776-60,555N/A12/31/202365,547-2,647-34,206-28,362N/A9/30/202367,446-7,9511,2524,155N/A6/30/202397,25423,6085,5348,498N/A3/31/2023104,80336,1019,86312,230N/A12/31/202267,3013,20969,74672,132N/A9/30/202257,9944,35243,64544,605N/A12/31/20215,332-43,558-41,871-40,605N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A298380は今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.1% ) よりも高い成長率であると考えられます。収益対市場: A298380今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: A298380今後 3 年以内に収益を上げることが予想されます。収益対市場: A298380の収益 ( 11.1% ) KR市場 ( 15.5% ) よりも低い成長が予測されています。高い収益成長: A298380の収益 ( 11.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A298380 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 08:34終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ABL Bio Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Jisoo LeeDAOL Investment & Securities Co., Ltd.Haesoon KwonEugene Investment & Securities Co Ltd.Hee Ryeong JungKyobo Securities Co., Ltd1 その他のアナリストを表示
Breakeven Date Change • Mar 17No longer forecast to breakevenThe 5 analysts covering ABL Bio no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of ₩10.9m in 2027. New consensus forecast suggests the company will make a loss of ₩16.0m in 2027.
Major Estimate Revision • Nov 29Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩311 to ₩236 per share. Revenue forecast steady at ₩105.7m. Net income forecast to grow 54% next year vs 42% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩102,833 to ₩124,500. Share price rose 5.1% to ₩188,000 over the past week.
Breakeven Date Change • Mar 17No longer forecast to breakevenThe 5 analysts covering ABL Bio no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of ₩10.9m in 2027. New consensus forecast suggests the company will make a loss of ₩16.0m in 2027.
お知らせ • Mar 17ABL Bio Inc., Annual General Meeting, Mar 27, 2026ABL Bio Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 456, bongeunsa-ro, gangnam-gu, seoul South Korea
New Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (₩16b net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Jan 28New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: ₩29b Forecast net loss in 2 years: ₩13b This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (₩13b net loss in 2 years).
お知らせ • Jan 09ABL Bio Inc. announced that it has received KRW 21.7244227 billion in funding from Eli Lilly and CompanyOn January 9, 2026, ABL Bio Inc. closed the transaction. The company issued 172,553 common shares at an issue price of KRW 125,900 for gross proceeds of KRW 21,724,422,700.
Major Estimate Revision • Nov 29Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩311 to ₩236 per share. Revenue forecast steady at ₩105.7m. Net income forecast to grow 54% next year vs 42% growth forecast for Biotechs industry in South Korea. Consensus price target up from ₩102,833 to ₩124,500. Share price rose 5.1% to ₩188,000 over the past week.
Reported Earnings • Nov 13Third quarter 2025 earnings released: ₩395 loss per share (vs ₩274 loss in 3Q 2024)Third quarter 2025 results: ₩395 loss per share (further deteriorated from ₩274 loss in 3Q 2024). Revenue: ₩1.44b (down 82% from 3Q 2024). Net loss: ₩21.3b (loss widened 62% from 3Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: ₩820 (vs ₩238 loss in 2Q 2024)Second quarter 2025 results: EPS: ₩820 (up from ₩238 loss in 2Q 2024). Revenue: ₩75.7b (up ₩67.3b from 2Q 2024). Net income: ₩39.8b (up ₩51.2b from 2Q 2024). Profit margin: 53% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 153 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 08Health Check: How Prudently Does ABL Bio (KOSDAQ:298380) Use Debt?KOSDAQ:A298380 1 Year Share Price vs Fair Value Explore ABL Bio's Fair Values from the Community and select yours...
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
分析記事 • Mar 26ABL Bio (KOSDAQ:298380) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Mar 15Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩1,156 loss per share (further deteriorated from ₩55.00 loss in FY 2023). Revenue: ₩33.4b (down 49% from FY 2023). Net loss: ₩55.5b (loss widened ₩52.9b from FY 2023). Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Mar 14ABL Bio Inc., Annual General Meeting, Mar 28, 2025ABL Bio Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 20, pangyo-ro 289beon-gil, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Nov 20Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%ABL Bio Inc. ( KOSDAQ:298380 ) shares have had a horrible month, losing 30% after a relatively good period beforehand...
Reported Earnings • Nov 14Third quarter 2024 earnings released: ₩1,095 loss per share (vs ₩86.00 loss in 3Q 2023)Third quarter 2024 results: ₩1,095 loss per share (further deteriorated from ₩86.00 loss in 3Q 2023). Revenue: ₩7.94b (down 7.4% from 3Q 2023). Net loss: ₩52.5b (loss widened ₩48.4b from 3Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 36% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩238 loss per share (vs ₩217 loss in 2Q 2023)Second quarter 2024 results: ₩238 loss per share (further deteriorated from ₩217 loss in 2Q 2023). Revenue: ₩8.44b (down 1.7% from 2Q 2023). Net loss: ₩11.4b (loss widened 10% from 2Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in South Korea.
分析記事 • May 29Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Apr 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 74% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).
Reported Earnings • Mar 19Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: ₩55.00 loss per share (down from ₩67.00 profit in FY 2022). Revenue: ₩65.5b (down 2.6% from FY 2022). Net loss: ₩2.65b (down 183% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.8%. Revenue is expected to decline by 44% p.a. on average during the next 2 years, while revenues in the Biotechs industry in South Korea are expected to grow by 18%.
分析記事 • Feb 26Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Jan 29New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 81% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩18,830, the stock trades at a trailing P/E ratio of 38.2x. Average forward P/E is 42x in the Biotechs industry in South Korea. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩16,520, the stock trades at a trailing P/E ratio of 33.5x. Average forward P/E is 34x in the Biotechs industry in South Korea. Total loss to shareholders of 32% over the past three years.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩20,750, the stock trades at a trailing P/E ratio of 42.1x. Average forward P/E is 42x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.
お知らせ • Aug 05ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific AntibodyABL Bio Inc. announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea'sMinistry of Food and Drug Safety (MFDS). The Phase 1 clinical trial is an open-label, multi-center dose escalation and dose expansion study designed to evaluate the safety, tolerability, maximum tolerated dose (MTD) and preliminary efficacy of ABL501 in patients with advanced or metastatic solid tumors. ABL501 uses Grabody-I platform technology to simultaneously block PD-L1 and LAG-3-mediated T cell inhibition. Preclinical results demonstrate a synergistic increase of T cell activation that is higher than the enhancements induced by combination of anti-PD-L1 and LAG-3. ABL501 also showed a good safety profile in monkeys.
分析記事 • Mar 31We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Feb 17New 90-day low: ₩21,400The company is down 17% from its price of ₩25,800 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
分析記事 • Jan 20Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...
分析記事 • Dec 16Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 17New 90-day low: ₩22,300The company is down 27% from its price of ₩30,700 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: ₩27,550The company is down 5.0% from its price of ₩29,050 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.